Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of age and genetic variations in VKORC1, CYP2C9 and CYP3A4 on the phenprocoumon dose in pediatric patients.

Pharmacogenomics - 1 Oct 2018

Maagdenberg Hedy, Bierings Marc B, van Ommen C Heleen, van der Meer Felix Jm, Appel Inge M, Tamminga Rienk Yj, Cessie Saskia le, Swen Jesse J, der Straaten Tahar van, Boer Anthonius de, Maitland-van der Zee Anke H

Abstract excerpt

AIM: To study the effects of clinical and genetic factors on the phenprocoumon dose requirement in pediatric patients and to develop a dosing algorithm. METHODS: Pediatric patients who used phenprocoumon were invited to participate in a retrospective follow-up study. Clinical information and genotypes of genetic variations in CYP2C9, VKORC1, CYP4F2, CYP2C18 and CYP3A4 were collected and tested with linear...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to Anticoagulants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Cytochrome P-450 CYP3A

Share to Follow-Up Studies

Share to Infant

Share to Pharmacogenetics

Share to Vitamin K Epoxide Reductases

Source

Identifiers

PMID: 30207196
DOI: 10.2217/pgs-2018-0095

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of age and genetic variations in VKORC1, CYP2C9 and CYP3A4 on the phenprocoumon dose in pediatric patients.PMID 30207196Read ↗

In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes.Semantic proximity Read ↗

VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children.Semantic proximity Read ↗

A new algorithm for weekly phenprocoumon dose variation in a southern Brazilian population: role for CYP2C9, CYP3A4/5 and VKORC1 genes polymorphisms.Semantic proximity Read ↗

The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population.Semantic proximity Read ↗

The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric population.Semantic proximity Read ↗

VKORC1 -1639G>A and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement.Semantic proximity Read ↗

Effect of VKORC1, CYP2C9, CFP4F2, and GGCX Gene Polymorphisms on Warfarin Dose in Japanese Pediatric Patients.Semantic proximity Read ↗

The pediatric acenocoumarol dosing algorithm: the Children Anticoagulation and Pharmacogenetics Study.Semantic proximity Read ↗

Frequency of CYP2C9 and VKORC1 gene polymorphisms and their influence on warfarin dose in Egyptian pediatric patients.Semantic proximity Read ↗

Characterizing variability in warfarin dose requirements in children using modelling and simulation.Semantic proximity Read ↗

VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.Semantic proximity Read ↗

Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.